126 related articles for article (PubMed ID: 9181761)
1. Pharmacological preconditioning of ischaemia.
Laghi Pasini F; Capecchi PL; Acciavatti A; Petri S; de Lalla A; Cati G; Colafati M; Di Perri T
Clin Hemorheol Microcirc; 1997; 17(1):73-84. PubMed ID: 9181761
[TBL] [Abstract][Full Text] [Related]
2. [Vascular and hemorheologic effects of buflomedil chlorhydrate in chronic obliterative arteriopathies of the legs].
Coglitore S; Manganaro A; Barbera MC; Cento D; Buda D; Arrigo F; Consolo F
Minerva Cardioangiol; 1986 Nov; 34(11):745-9. PubMed ID: 2949163
[No Abstract] [Full Text] [Related]
3. [Action and tolerability of delayed-action buflomedil in obliterating arteriopathies of the lower limbs. A multicenter study].
Andreozzi GM; Lepore R
Clin Ter; 1990 Nov; 135(4):273-81. PubMed ID: 2150026
[TBL] [Abstract][Full Text] [Related]
4. Experimental model of short-time exercise-induced preconditioning in POAD patients.
Capecchi PL; Pasini FL; Cati G; Colafati M; Acciavatti A; Ceccatelli L; Petri S; de Lalla A; Di Perri T
Angiology; 1997 Jun; 48(6):469-80. PubMed ID: 9194532
[TBL] [Abstract][Full Text] [Related]
5. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
Joffre F; Meites G; Rousseau H; Staffin C; Allaert FA; Pelat P
Ann Radiol (Paris); 1994; 37(3):239-44. PubMed ID: 8092756
[TBL] [Abstract][Full Text] [Related]
6. Positive effect of oral buflomedil on exercise-induced haemorheological damage and on claudication distance in peripheral obliterative arterial disease patients.
Forconi S; Pieragalli D; Acciavatti A; Del Bigo C; Galigani C; Ralli L; Guerrini M; Di Perri T
J Int Med Res; 1984; 12(3):188-92. PubMed ID: 6734922
[No Abstract] [Full Text] [Related]
7. Clinical and circulatory effects of Iloprost either administered for 1 week or 4 weeks in patients with peripheral obstructive arterial disease at Leriche-Fontaine stage III.
Arosio E; Sardina M; Prior M; De Marchi S; Zannoni M; Bianchini C
Eur Rev Med Pharmacol Sci; 1998; 2(2):53-9. PubMed ID: 10229559
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of chronic obliterative arteriopathy of the legs in the second Fontaine's stage. Personal experience with a buflomedil-pentoxifylline-defibrotide combination].
Marci M; Albiani B; Ricci M; Russo F
Clin Ter; 1995 Mar; 146(3):211-4. PubMed ID: 7789083
[TBL] [Abstract][Full Text] [Related]
9. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
Spitzer S; Bach R; Schieffer H
Int Angiol; 1992; 11(3):204-10. PubMed ID: 1460355
[TBL] [Abstract][Full Text] [Related]
10. [Doppler flowmeter evaluation of the effects of the administration of buflomedil (irrodan) on peripheral circulation in patients with obstructive chronic arteriopathy].
Abate S; Ferulano GP; Vanni L; Dilillo S; Picilli M; D'Alessio E
Minerva Cardioangiol; 1985 Nov; 33(11):749-56. PubMed ID: 2935748
[No Abstract] [Full Text] [Related]
11. Effects of PGE-1 in patients suffering from peripheral arterial occlusive disease.
Milio G; Cospite V; Cospite M
Minerva Cardioangiol; 2003 Jun; 51(3):311-6. PubMed ID: 12867883
[TBL] [Abstract][Full Text] [Related]
12. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
Lucisano V; Margheriti R; Matone P; Morrieri C; Rugolo A; Corsi V
Clin Ter; 1986 Jun; 117(6):499-509. PubMed ID: 3527536
[No Abstract] [Full Text] [Related]
13. Protective effect of ischaemic preconditioning against ischaemia-induced reperfusion injury of skeletal muscle: how many preconditioning cycles are appropriate?
Saita Y; Yokoyama K; Nakamura K; Itoman M
Br J Plast Surg; 2002 Apr; 55(3):241-5. PubMed ID: 12041979
[TBL] [Abstract][Full Text] [Related]
14. [Digital blood flow in peripheral vascular diseases. Action of drugs: buflomedil].
Frausini G; Rotatori P; Gaggi S; Barone A; Pupita F
Minerva Cardioangiol; 1988 Jun; 36(6):319-22. PubMed ID: 3211330
[No Abstract] [Full Text] [Related]
15. [Buflomedil chlorhydrate in peripheral vasculopathies].
Dall'Antonia F; Perbellini A; Adami CA; Dal Cortivo G; Bucci S
Clin Ter; 1986 Dec; 119(5):379-85. PubMed ID: 2951055
[No Abstract] [Full Text] [Related]
16. Protective effect of preconditioning and adenosine pretreatment in experimental skeletal muscle reperfusion injury.
Papanastasiou S; Estdale SE; Homer-Vanniasinkam S; Mathie RT
Br J Surg; 1999 Jul; 86(7):916-22. PubMed ID: 10417565
[TBL] [Abstract][Full Text] [Related]
17. [Buflomedil in arterial occlusive disease. Results of a controlled study].
Trübestein G; Balzer K; Bisler H; Klüken N; Mahfoud Y; Müller-Wiefel H; Unkel B; Ziegler W
Dtsch Med Wochenschr; 1982 Dec; 107(51-52):1957-61. PubMed ID: 6756854
[No Abstract] [Full Text] [Related]
18. [Clinical experimentation with a new vasodilator: cinepazide maleate in arterial diseases of the lower limbs].
Warembourg G; Carre A; Ginestet A; Lambert M
Lille Med; 1976 Dec; 21 Suppl 4():898-901. PubMed ID: 1018614
[No Abstract] [Full Text] [Related]
19. Effects of buflomedil in a group of patients with chronic peripheral arterial diseases. Clinical and hemorheological evaluation.
Mozzi E; Chiurazzi D; Spinola A; Annoni F; Germiniani R
J Int Med Res; 1985; 13(6):317-21. PubMed ID: 4076530
[TBL] [Abstract][Full Text] [Related]
20. Increase in plasma levels of adenosine and adenine nucleotides after intravenous infusion of buflomedil in humans.
Capecchi PL; Laghi Pasini F; Sodi N; Chiavetta M; Sensi S; De Lalla A; Volpi L; Di Perri T
J Cardiovasc Pharmacol; 1995 Jan; 25(1):35-9. PubMed ID: 7723351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
